A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Cours

A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) is a phase 2, randomised interventional study registered as NCT07669220 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 76 participants, started 2026-01-01 and due to reach its primary completion in 2028-01-01. Interventions recorded: Short-course Radiotherapy, SCRT; Toripalimab. Conditions listed: Rectal Adenocarcinoma; High-risk Locally Advanced; Short-course Radiotherapy (SCRT); Immunotherapy; FOLFOX. Primary outcome: CCR. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed pMMR/MSS rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.